anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled composition, obtained by incorporating urokinase liposome containing a higher fatty acid added thereto with an absorption accelerator, e.g. a higher fatty acid, polyalkylene glycol, calcium, etc., and capable of enhancing absorption through intestinal tracts by oral administration, and retaining effective concentration in blood for a long time. CONSTITUTION:An intestinally absorbable urokinase liposome composition consisting of liposome incorporating urokinase and an absorption accelerator, e.g. polyalkylene glycol, calcium or higher fatty acid. The membrane material constituting the above-mentioned liposome contains lipid, e.g. hydrogenated phospholipid, and at least one higher fatty acid, e.g. capric acid. The urokinase is decomposed and inactivated in stomach in oral administration and has low absorption efficiency through intestinal tracts as an enteric agent, but the disintegration is controlled by using the membrane material of the above-mentioned liposome. The incorporation of the above-mentioned absorption accelerator enhances remarkably the intestinal absorption, and a high concentration in blood is maintained.
PURPOSE: A composition containing Melandrii Herba ethanol extract and a functional food are provided to suppress the growth of lung cancer cells and to effectively prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Melandrii Herba ethanol extract as an active ingredient. The ethanol is 95% ethanol. The composition contains pharmaceutically acceptable carrier or diluents. A functional food for preventing lung cancer contains the ethanol extract as an active ingredient, containing sitologically acceptable food additive. [Reference numerals] (AA) Melandrii Herba
The role of the Wnt/β-catenin signaling pathway in epilepsy and the effects of its modulators as efficacious treatment options, though postulated, has not been sufficiently investigated. We evaluated the involvement of β-catenin and GSK-3β, the significant proteins in this pathway, in the lithium chloride-pilocarpine-induced status epilepticus model in rodents to study acute phase of temporal lobe epilepsy (TLE). The modulators studied were 6-BIO, a GSK-3β inhibitor and Sulindac, a Dvl protein inhibitor. The disease group exhibited increased seizure score and seizure frequency, and the assessment of neurobehavioral parameters indicated notable alterations. Furthermore, histopathological examination of hippocampal brain tissues revealed significant neurodegeneration. Immunohistochemical study of hippocampus revealed neurogenesis in 6-BIO and sulindac groups. The gene and protein expression by RT-qPCR and western blotting studies indicated Wnt/β-catenin pathway downregulation and increased apoptosis in the acute phase of TLE. 6-BIO was very efficient in upregulating the Wnt pathway, decreasing neuronal damage, increasing neurogenesis in hippocampus and decreasing seizure score and frequency in comparison to sulindac. This suggests that both GSK-3β and β-catenin are potential and novel drug targets for acute phase of TLE, and treatment options targeting these proteins could be beneficial in successfully managing acute epilepsy. Further evaluation of 6-BIO to explore its therapeutic potential in other models of epilepsy should be conducted.
PURPOSE: A tooth patch which is attached on teeth, containing phytoncide is provided to remove foreign materials from teeth and to remove bad breath. CONSTITUTION: A tooth patch used for removing bad breath contains 0.1-20 wt% of phytoncide extracted from cypress timber. The tooth patch also prevents dental cavity and periodontal diseases. The tooth patch comprises a support layer and a teeth adhering layer which is easily attached or adhered to teeth or gingival. The teeth adhering layer is formed of alginate, xanthane gum, and hydrogypropyl cellulose polysaccharides. A polymer used for the support layer is polyvinyl acetate, ethyl cellulose, polymethyl methacrylate, methacrylic acid copolymers, methacryl copolymers, aminoalkyl methacrylate copolymers, cellulose acetate phthalate, shellac, polyethylene, PVC, and polyurethane. [Reference numerals] (AA) Embodiment 1; (BB) Embodiment 2; (CC) Comparative embodiment 1; (DD) Change of halimeter value after attaching tooth patch; (EE) 170 reduction; (FF) 220 reduction; (GG) 40 reduction
The QuantiFERON CMV (QCMV) test evaluates specific adaptive immune system activity against CMV by measuring IFN-γ released by activated CD8+ T lymphocytes. We aimed to evaluate the QCMV test as a predictive tool for CMV manifestations and acute or chronic lung allograft rejection (AR and CLAD) in lung transplant (LTx) patients. A total of 73 patients were divided into four groups based on donor and recipient (D/R) serology for CMV and QCMV assay: group A low-risk for CMV infection and disease (D-/R-); group B and C at intermediate-risk (R+), group B with non-reactive QCMV and group C with reactive QCMV; group D at high-risk (D+/R-). Group D patients experienced higher viral replication; no differences were observed among R+ patients of groups B and C. D+/R- patients had a higher number of AR events and group C presented a lower incidence of AR. Prevalence of CLAD at 24 months was higher in group B with a higher risk of CLAD development (OR 6.33). The QCMV test allows us to identify R+ non-reactive QCMV population as the most exposed to onset of CLAD. This population had a higher, although non-significant, susceptibility to AR compared to the R+ population with reactive QCMV.
OBJECTIVE: Long COVID can include impaired cognition ('brain fog'; a term encompassing multiple symptoms) and mental health conditions. We performed a systematic review and meta-analysis to estimate their prevalence and to explore relevant factors associated with the incidence of impaired cognition and mental health conditions.
METHODS: Searches were conducted in Medline and PsycINFO to cover the start of the pandemic until August 2023. Included studies reported prevalence of mental health conditions and brain fog in adults with long COVID after clinically-diagnosed or PCR-confirmed SARS-CoV-2 infection.
FINDINGS: 17 studies were included, reporting 41,249 long COVID patients. Across all timepoints (3-24 months), the combined prevalence of mental health conditions and brain fog was 20·4% (95% CI 11·1%-34·4%), being lower among those previously hospitalised than in community-managed patients(19·5 vs 29·7% respectively; p = 0·047). The odds of mental health conditions and brain fog increased over time and when validated instruments were used. Odds of brain fog significantly decreased with increasing vaccination rates (p = ·000).
CONCLUSIONS: Given the increasing prevalence of mental health conditions and brain fog over time, preventive interventions and treatments are needed. Research is needed to explore underlying mechanisms that could inform further research in development of effective treatments. The reduced risk of brain fog associated with vaccination emphasizes the need for ongoing vaccination programs.
A system for entering and monitoring dietary data for use with a computer includes a handheld electronic device having an input mechanism for inputting dietary data. The handheld device may be interfaced with the computer for communication therebetween. The system includes software for operation upon the computer, which includes instructions for retrieving the dietary information from the electronic device. The computer includes a printer and display and the software includes instructions enabling the dietary information to be analyzed and for the analyzed data to be displayed graphically on the display. Nutritional data may also be printed as a barcode for application to a label or restaurant menu. Dietary data, in the form of recipes or recipe libraries, may be input directly into the computer and then uploaded to the electronic device for user selection. The system provides storage, analysis, and comparisons of actual consumption and target consumption data.
Leukocytospermia can lead to decreased spermatozoa motility, increased spermatozoa morphological abnormalities, elevated spermatozoa DNA fragmentation index, impairment of the spermatozoa acrosome function, and even affected embryonic development. It is a common andrological disease in clinical practice and one of the important causes of male infertility. When determining whether male reproductive tract inflammation exists, andrologists often choose to examine round cells or seminal plasma elastase in the semen as a clinical diagnostic basis. However, the examination of round cells is easily influenced by sloughed spermatogenic cells and reproductive tract epithelial cells, which do not contribute to reducing the indiscriminate and unnecessary use of antibiotics. At the same time, the detection process of elastase is relatively complicated, time-consuming, and slow in reporting results, which is not beneficial for early diagnosis and treatment of diseases such as male genital tract infections (MGTIs). We have innovatively applied the examination of peroxidase-positive leukocytes in semen assisted by a computer-assisted semen analysis (CASA) system as a diagnostic criterion for leukocytospermia, successfully solving these problems. This examination only requires the addition of the operating fluid consisting of four reagents into the specimen, and the total reaction time at room temperature can be controlled within 20-30 min. With the subsequent smear and microscopic examination, the concentration of peroxidase-positive leukocytes in semen can be obtained within a total of 60 min, which can be used to diagnose whether the inflammation of the male reproductive tract existed.
Rapid maxillary expansion (RME) treatment has been used widely since the mid 1960s. It is frequently used to correct maxillary width deficiency, posterior crossbite or to expand arch perimeters to alleviate dental crowding or patients with Class III malocclusion who often are treated with RME because of an insufficient maxillary arch width. Although, the major effect of this treatment is noticed clinically in the dentition and maxilla area. RME therapy appears to involve an ample portion of the craniofacial complex, as the maxilla is associated with 10 bones in the face and head. Although, the RME force is concentrated on widening the maxilla, concomitant changes occur in circumaxillary sutures. Moreover, it has been claimed that the transverse forces generated during rapid maxillary expansion are transmitted, via the pterygomaxillary connection, to the unpaired sphenoid bone of the cranial base, where they lead to stress. The extent and effects of this have not yet been studied extensively, nor have they been well determined. In orthodontics, the cranial base has received attention because of the fact that its growth influences the maxillary-mandibular complex. Some authors in fact consider the cranial base as a guide rail for development of the maxilla, midface, and lower facial complex. This involvement has been hypothesized following investigations based on histologic methods, radiologic imaging, photoelastic models, bone scintigraphy, and finite element analysis. However, even though the above studies have been well designed, some issues may have affected their conclusions. In fact, histological findings are limited to experimental studies in animals. Moreover, accuracy of the results of the finite element model (FEM) depends on the detailed geometry, material properties, and boundary conditions of the FEM. Therefore, until now, there have been only speculations about whether RME can or cannot disarticulate these structures in humans. With advanced technology and the introduction of three-dimensional computed tomography imaging, that allow clinicians and researchers to quantitatively evaluate bone changes with minimal distortion and lower radiation dosage, Due to the high dose of x-ray of CT, high cost and the lack of study on the effect of the RME on circumaxillary sutures and spheno-occipital synchondrosis using imaging three-dimensional radiographic (CT). Because of the importance of the effect of the maxillary expansion on maxillary displacement, and the resulting significant clinical effects, especially at the level of improvement in the third class at the children. From here stems the need for this study on the effect of rapid maxillary expansion RME on the craniofacial sutures in children using cone beam computed tomography
Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
Chromosome analysis (CA) and chromosomal microarray analysis (CMA) have been successfully used to diagnose genetic disorders. However, many conditions remain undiagnosed due to limitations in resolution (CA) and detection of only unbalanced events (CMA). Optical genome mapping (OGM) has the potential to address these limitations by capturing both structural variants (SVs) resulting in copy number changes and balanced rearrangements with high resolution. In this study, we investigated OGM's concordance using 87 SVs previously identified by CA, CMA, or Southern blot. Overall, OGM was 98% concordant with only three discordant cases: (1) uncalled translocation with one breakpoint in a centromere; (2) uncalled duplication with breakpoints in the pseudoautosomal region 1; and (3) uncalled mosaic triplication originating from a marker chromosome. OGM provided diagnosis for three previously unsolved cases: (1) disruption of the SON gene due to a balanced reciprocal translocation; (2) disruption of the NBEA gene due to an inverted insertion; (3) disruption of the TSC2 gene due to a mosaic deletion. We show that OGM is a valid method for the detection of many types of SVs in a single assay and is highly concordant with legacy cytogenomic methods; however, it has limited SV detection capabilities in centromeric and pseudoautosomal regions.
The present invention relates to disulfide-stabilized recombinant polypeptid e molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V H and V L regions of the Fv fragment. The .alpha. and .beta . chains of T cells receptors may be similarly stabilized by means described in the invention.
Lung diseases have profound effects on the aging population. We aimed to hypothesize and investigate the effect of remote pulmonary telerehabilitation and motor imagery (MI) and action observation (AO) methods on the clinical status of elderly chronic obstructive pulmonary disease (COPD) patients. Twenty-six patients were randomly assigned to pulmonary telerehabilitation (PtR) or cognitive telerehabilitation (CtR) groups. The programs were carried out 3 days a week for 8 weeks. The 6-min walk test (6MWT), modified Medical Research Council dyspnea score, blood lactate level (BLL), measurement of peripheral muscle strength (PMS), and electromyography activation levels of accessory respiratory muscles were the main outcomes. There was a statistically significant improvement (p < 0.05) in both groups in the 6MWT distance and in secondary results, except for BLL. Generally, in the mean muscle activity obtained from the electromyography measurement after the program, there were statistically significant increases in the PtR group and decreases in the CtR group (p < 0.05). There was a statistically significant increase in PMS in both groups. An active muscle-strengthening program has the same benefits as applying the muscle-strengthening program to the patient as MI and AO. CtR can be a powerful alternative rehabilitation method in respiratory patients who cannot tolerate active exercise programs.
Adipose tissue is the first and primary target organ of obesity and the main source of circulating miRNAs in patients with obesity. This systematic review aimed to analyze and summarize the generation and mechanisms of adipose-derived miRNAs and their role as early predictors of various obesity-related complications. Literature searches in the PubMed and Web of Science databases using terms related to miRNAs, obesity, and adipose tissue. Pre-miRNAs from the Human MicroRNA Disease Database, known to regulate obesity-related metabolic disorders, were combined for intersection processing. Validated miRNA targets were sorted through literature review, and enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes via the KOBAS online tool, disease analysis, and miRNA transcription factor prediction using the TransmiR v. 2.0 database were also performed. Thirty miRNAs were identified using both obesity and adipose secretion as criteria. Seventy-nine functionally validated targets associated with 30 comorbidities of these miRNAs were identified, implicating pathways such as autophagy, p53 pathways, and inflammation. The miRNA precursors were analyzed to predict their transcription factors and explore their biosynthesis mechanisms. Our findings offer potential insights into the epigenetic changes related to adipose-driven obesity-related comorbidities.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of pharmaceutical industry, in particular to method of obtaining system of targeted drug delivery for introduction of pharmaceutically active substance into central nervous system of mammals through hematoencephalic barrier. System contains poly(DL-lactide) and/or poly(DL-lactide-soglycolide)-based nanoparticles, pharmacologically active substance, absorbed, adsorbed and/or included into nanoparticles, and contains TPGS or has coating from surface-active substance pluronic 188, which is precipitated on drug-filled nanoparticles. Described are methods of obtaining system of targeted drug delivery and application of system of targeted drug delivery for treatment of CNS disease or disorder. ^ EFFECT: elaboration of efficient method of obtaining system of targeted drug delivery for introduction of pharmacologically active substance into central nervous system of mammals through hematoencephalic barrier. ^ 20 cl, 14 ex, 2 dwg
Human Experience

There is no clinical experience with overdosage with CONTRAVE. The maximum daily dose of CONTRAVE administered in clinical trials contained 50 mg naltrexone and 400 mg bupropion. The most serious clinical implications of CONTRAVE overdose are likely those related to overdose of bupropion.

Overdoses of up to 30 grams or more of bupropion (equivalent of up to 83 times the recommended daily dose of CONTRAVE 32 mg/360 mg) have been reported. Seizure was reported in approximately one third of all cases. Other serious reactions reported with overdoses of bupropion alone included hallucinations, loss of consciousness, sinus tachycardia, and ECG changes such as conduction disturbances (including QRS prolongation) or arrhythmias. Fever, muscle rigidity, rhabdomyolysis, hypotension, stupor, coma, and respiratory failure have been reported mainly when bupropion was part of multiple drug overdoses.

Although most patients recovered without sequelae, deaths associated with overdoses of bupropion alone have been reported in patients ingesting large doses of the drug. Multiple uncontrolled seizures, bradycardia, cardiac failure, and cardiac arrest prior to death were reported in these patients.

There is limited experience with overdose of naltrexone monotherapy in humans. In one study, subjects who received 800 mg naltrexone daily (equivalent to 25 times the recommended daily dose of CONTRAVE 32 mg/360 mg) for up to one week showed no evidence of toxicity.

Animal Experience

In the mouse, rat, and guinea pig, the oral LD50s for naltrexone were 1,100 to 1,550 mg/kg; 1,450 mg/kg; and 1,490 mg/kg; respectively. High doses of naltrexone (generally greater than or equal to 1,000 mg/kg) produced salivation, depression/reduced activity, tremors, and convulsions. Mortality in animals due to high-dose naltrexone administration usually was due to clonic-tonic convulsions and/or respiratory failure.

Overdosage Management

If over-exposure occurs, call your poison control center at 1-800-222-1222. There are no known antidotes for CONTRAVE. In case of an overdose, provide supportive care, including close medical supervision and monitoring. Consider the possibility of multiple drug overdose. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Induction of emesis is not recommended.
A solutions of an inhalation medicament is packaged in a sealed dispenser containing a pressurised gas and provided with a one-way outlet valve, eg a metering valve. The dispenser may be prepared by introducing the solution and the pressurised gas into the dispenser under sterile conditions. Alternatively, the dispenser may be sterilised after introduction of the solution and gas. After being dispensed from the dispenser, the solution can be administered by nebulisation. A particularly preferred solution for use in conjunction with the dispensers contains sodium cromoglycate and chlorbutol. This solution is indicated for use in the treatment of reversible obstructive airways disease. An aqueous solution of sodium cromoglycate and chlorbutol is prepared by dissolving the chlorbutol in distilled water at a temperature of 20-60 DEG C in a covered or sealed vessel and admixing the resulting solution with solid sodium cromoglycate.
An early rhythm stabilization is the primary focus of the current treatment of atrial fibrillation. Based on current studies catheter ablation of pulmonary vein isolation (PVI) is an established component in the treatment of atrial fibrillation. Therefore, in the management of affected patients this procedure should be offered at an early stage in addition to the holistic treatment approach with consistent treatment of cardiovascular risk factors and thromboembolism prophylaxis with anticoagulants. Substances with an antiarrhythmic effect can be included in a supportive role in the management of atrial fibrillation. Pharmacotherapy could also perspectively play an important role in the treatment of the underlying atrial cardiomyopathy of the phenotype of atrial fibrillation. An understanding of the atrial pathophysiology of individual patients with adapted selection of suitable treatment strategies of ablation up to pharmacotherapy is decisive for the successful antiarrhythmic outcome. The decision on the treatment strategy must always be individually made together with the affected patient. The advantages and disadvantages of both options must be explained in detail and pre-existing comorbidities and risk factors must be included. Additionally, the individual wishes of the patient must be taken into account.
Neuronal Ceroid Lipofuscinosis (NCL) is the most common neurodegenerative disorder in children characterized by seizures, blindness, ataxia, myoclonia and loss of cognition. There are 12 clinical types identified with a concurrent genetic abnormality. The diagnosis is determined by gene testing and skin biopsy findings although genetic testing has supplanted skin biopsy in most cases. Numberous studies have confirmed the presence of sleep disorder in patients with NCL but these cases were documented over a decade ago. The investigators would like to study the prevalence of sleep disorders in this group of patients. The investigators will distribute a Children's Sleep Habits Questionnaire (CSHQ) to the family of the patient to complete and provide a information regarding the patient's sleep. In addition to the validated sleep questionnaire a separate demographic questionnaire will be given to the family to identify the type of NCL, presence or absence of blindness, presence or absence of seizures, interventions tried to treat sleep disturbance. The last questions of the study are asking for the presence or absence of Restless Leg Syndrome symptoms.